{
  "age": 45,
  "sex": "female",
  "cancer_type": "melanoma",
  "biomarkers": ["BRAF V600E"],
  "description": "45-year-old female with metastatic cutaneous melanoma, BRAF V600E mutated. Primary on left lower extremity (Breslow 2.8mm) resected 2023. Developed lung and subcutaneous metastases 8 months later. First-line dabrafenib/trametinib achieved partial response but progressed at 14 months. Second-line nivolumab/ipilimumab combination - mixed response, eventually progressed with new splenic lesions. Currently well-appearing with good functional status. LDH elevated (312). Looking for novel combinations or emerging targets. No brain mets on most recent MRI.",
  "ecog_status": 0,
  "pd_l1_status": "60%",
  "prior_therapies": ["dabrafenib", "trametinib", "nivolumab", "ipilimumab"],
  "brain_mets_status": "none",
  "co_mutations": [],
  "country": "United States",
  "location_preference": ["United States"]
}

